Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.74 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.74 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.74 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | MTOR | P42345 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | HTR2C | P28335 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577138 | 1.00 | SLC6A4 (0.74) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL2690834 | 1.00 | SLC6A4 (0.74) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL6013735 | 0.96 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL6005053 | 0.87 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL5160113 | 0.86 | SLC7A5 (0.71) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL5160122 | 0.86 | SLC7A5 (0.71) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL6006305 | 0.85 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL6004122 | 0.85 | SLC6A9 (0.56) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| Seproxetine SCHEMBL272873 | 0.85 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL7056582 | 0.85 | SLC6A4 (0.74) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024084517-A1 | 3-PHENYL-3-(ARYLOXY) PROPAN-1-AMINES AND THE PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2024-04-25 | — | — | WO | disclosed |
| US-8168635-B2 | 2-(aminomethyl)-5-phenyltetrahydrofuran; 4-(3,4-Dimethoxyphenyl)-2-[5-(2-{5-[2-(5-fluoro-2-methoxyphenyl)-ethyl]-tetrahydrofuran-2-yl}-ethylamino)-pentyl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one; dual inhibitor of serotonin reuptake and phosphodiesterase 4 (PDE4) enzyme activity | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-05-01 | — | — | US | disclosed |
| US-20080261967-A1 | Modulators of Central Nervous System Neurotransmitters | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2008-10-23 | — | — | US | disclosed |
| US-20060287298-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. | 2006-12-21 | — | — | US | disclosed |
| EP-1014966-B1 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | ALLELIX NEUROSCIENCE INC (US) | 2006-08-02 | — | — | EP | disclosed |
| US-7019024-B2 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20010012857-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | NPS PHARMACEUTICALS, INC. | 2001-08-09 | — | — | US | disclosed |
| US-6191165-B1 | ANTIDEPRESSANTS; SCHIZOPHRENIA; ALZHEIMER'S DISEASE; ANTIEPILEPTIC AGENTS | ALLELIX NEUROSCIENCE INC. | 2001-02-20 | — | — | US | disclosed |
| US-5929247-A | METHODS OF SYNTHESIZING 1,2,5-THIADIAZOLE COMPOUNDS SUCH AS 3-PROPYLTHIO-4-HYDROXY-1,2,5-THIADIAZOLE, USEFUL IN TREATING DISEASES IN THE CENTRAL NERVOUS SYSTEM CAUSED BY MUSCARINIC CHOLINERGIC SYSTEM MALFUNCTIONING | ELI LILLY AND COMPANY (US) | 1999-07-27 | — | — | US | disclosed |
| US-5852037-A | Method for treating anxiety | ELI LILLY AND COMPANY (US) | 1998-12-22 | — | — | US | disclosed |
| US-5821370-A | MUSCARINIC CHOLINERGIC DRUGS | ELI LILLY AND COMPANY (US) | 1998-10-13 | — | — | US | disclosed |
| US-5821371-A | 1,2,5-THIADIAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM CAUSED BY MALFUNCTIONING OF THE MUSCARINIC CHOLINERGIC SYSTEM; COGNITION ACTIVATORS; ALZHEIMER'S DISEASE | ELI LILLY AND COMANY (US) | 1998-10-13 | — | — | US | disclosed |
| US-5672709-A | INTERMEDIATES FOR DRUGS USEFUL IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-09-30 | — | — | US | disclosed |
| US-5665745-A | 1,2,5-THIADIAZOLE DERIVATIVES FOR TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | ELI LILLY AND COMPANY (US) | 1997-09-09 | — | — | US | disclosed |
| US-5646289-A | REACTING A 3-CHLORO-1,2,5-THIADIAZOLE WITH ALKALI METAL BIS(TRIALKYL OR ARYLSILYL)AMIDE; DECHLORINATION; TREATING NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1997017962-A1 | METHOD FOR TREATING ANXIETY | ELI LILLY AND COMPANY (US) | 1997-05-22 | — | — | WO | disclosed |
| EP-0774256-A1 | Use of azacyclic or azabicyclic thiadiazole compounds for treating anxiety | ELI LILLY AND COMPANY (US) | 1997-05-21 | — | — | EP | disclosed |
| EP-0709381-A1 | Heterocyclic compounds and their preparation and use | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
| US-4313896-A | ANTIDEPRESSANTS, PSYCHOTROPIC AGENTS | ELI LILLY AND COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261967-A1 | Modulators of Central Nervous System Neurotransmitters | GAP43, SLC18A2, CHRNA6 | SLC6A4 104/4885SLC6A2 47/4885SLC6A3 54/4885 |
| US-20060287298-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | SLC18A2, SLC6A1, SLC6A11 | SLC6A4 9/4885SLC6A2 4/4885SLC6A3 8/4885 |
| US-20010012857-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | SLC6A1, SLC18A2, SLC6A11 | SLC6A4 14/4885SLC6A2 5/4885SLC6A3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.